- Raised $350k funding round, Oct 2025
- Raised $3M funding round, Jul 2013
About
Vaxil BioTherapeutics is a clinical-stage company developing immunotherapeutic products, including long peptide vaccines and antibodies to treat cancer and infectious diseases. Vaxils products are derived from its fully owned proprietary technology, VaxHit, which uses the signal peptide domains in selected targets as core antigens. The companys lead product, ImMucin, has received EMA and FDA orphan drug designation for the treatment of multiple myeloma (MM) cancer. ImMucin has successfully completed a phase 1/2 clinical trial in 15 MM patients demonstrating a high safety profile and preliminary evidence for clinical efficacy. Vaxil is currently performing an additional phase 1/2 study with ImMucin in metastatic breast cancer patients being treated with first-line hormonal therapy. Vaxil has also isolated SPmAb-2.1 and SPmAb-6, which are anti-MUC1 SP antibodies with therapeutic and diagnostic properties that are potentially superior to other MUC1 antibodies. Vaxil further validated its VaxHit technology for anti-infective indications and isolated MTBuVax, a vaccine against mycobacterium tuberculosis that is currently in preclinical animal studies. Vaxil BioTherapeutics is a fully owned subsidiary of Vaxil Bio.
Funding history · 2 rounds · $6.3M total
Q&A
- What is Vaxil BioTherapeutics' primary focus?
- Vaxil BioTherapeutics is a clinical-stage company developing immunotherapeutic products, including long peptide vaccines and antibodies to treat cancer and infectious diseases.
- What is Vaxil BioTherapeutics' lead product and its current status?
- Vaxil BioTherapeutics' lead product, ImMucin, has received EMA and FDA orphan drug designation for multiple myeloma (MM) cancer. It has completed a phase 1/2 clinical trial in MM patients and is currently in an additional phase 1/2 study for metastatic breast cancer patients.
- What is the status of Vaxil BioTherapeutics' tuberculosis vaccine?
- Vaxil BioTherapeutics has isolated MTBuVax, a vaccine against mycobacterium tuberculosis, which is currently in preclinical animal studies.
- When was Vaxil BioTherapeutics founded?
- Vaxil BioTherapeutics was founded in February 2007.
- How many employees does Vaxil BioTherapeutics have?
- Vaxil BioTherapeutics has 1-10 employees.
- What is Vaxil BioTherapeutics' total funding raised to date?
- Vaxil BioTherapeutics has raised a total of $6,350,000 USD.
- When was Vaxil BioTherapeutics' most recent funding round?
- Vaxil BioTherapeutics' most recent funding round occurred in October 2025, raising $350,000 USD.
- Which investor participated in Vaxil BioTherapeutics' July 2013 funding round?
- Yorkville Advisors participated in Vaxil BioTherapeutics' funding round in July 2013.
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | vaxil-bio.com/cgi-sys/suspendedpage.cgi |
|---|---|
| linkedin.com/company/10579659 | |
| facebook.com/Vxlbio | |
| YouTube | youtube.com/channel/UC4i330YiJG7UplCSMluxMOw |
| instagram.com/vaxilbio |
Identifiers & details
| Founded | 2007-2 |
|---|---|
| Employees (exact) | 4 |
| Offices | Toronto |
| Status reason | Public on TASE on Mar 2016; |
Radar intelligence
Patents
| EPO | 5 |
|---|
Web history (Wayback)
| Domain | vaxil-bio.com |
|---|
Certificate / subdomain footprint
| Subdomains | 1 |
|---|